Clinical Outcomes in Patients Switched from Adalimumab to Baricitinib Due to Non-Response and/or Study Design: Phase III Data in Patients with Rheumatoid Arthritis
Ann Rheum Dis. 2019 Jul;78(7):890-898.
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Ann Rheum Dis. 2019 Jul;78(7):890-898.
Arthritis Rheumatol. 2019 Jul;71(7):1042-1055.
Arthritis Rheumatol. 2018 Dec;70(12):1923-1932. doi: 10.1002/art.40680
Please click the links below to go to the CSF review of each paper
Clinical Rheumatology 2018;37:2381–90 DOI 10.1007/s10067-018-4221-0
Ann Rheum Dis. 2018 Jul;77(7):988-995. DOI 10.1136/annrheumdis-2017-212461
Drug Safety 2018 Jul;41(7):645–53
Please click the links below to go to the CSF review of each paper.
Ann Rheum Dis 2017;76(11):1853-1861. doi: 10.1136/annrheumdis-2017-211259
J Rheumatol. 2018 Jan;45(1):14-21. doi: 10.3899/jrheum.161161